Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
The leading Advanced Merkel Cell Carcinoma Companies such as Xencor, Inc., Incyte Corporation, Millennium Pharmaceuticals, ...
3h
Hosted on MSNEMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...
Generating Insights and Increasing Transparency for Social Investment Ecosystem ...
1 (tie), Lauren Coughlin, Georgia Hall, Minjee Lee, Madelene Sagstrom, Maja Stark and Angel Yin, 2. 7, 33 tied with 1. 1 (tie), Jaravee Boonchant, In Gee Chun, Danielle Kang, Ruixin Liu, Ryann O'Toole ...
BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...
11h
Hosted on MSNModern Dragon Ball Would Be Unrecognizable if Akira Toriyama Ended the Series With Cell Like He Wanted ToHad Akira Toriyama ended the original run of the Dragon Ball manga as early as he would have liked, the entire franchise ...
Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results